Low molecular weight heparins as extended prophylaxis against recurrent thrombosis in cancer patients

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 7, 2008, Pages 637-645

  Engman, Cocav A ^a   Zacharski, Leo R ^a,b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Department of Veterans Affairs Regional Office White River Junction   (United States)

Author keywords

Cancer; Low molecular weight heparins; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; DALTEPARIN; DOCETAXEL; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTOMENADIONE; PLACEBO; RIVAROXABAN; TAMOXIFEN; TINZAPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HOSPITALIZATION; HUMAN; LONG TERM CARE; LUNG SMALL CELL CANCER; OUTPATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PHYSICIAN ATTITUDE; RECURRENT DISEASE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SURVIVAL RATE; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 49649114635     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0050     Document Type: Article

References (54)

1. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based base-control study. Arch Intern Med 2000;160:809-815.
2. Donati MB. Cancer and thrombosis. Haemostasis 1994;24:128-131.
3. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-291.
4. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632-634.
5. Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J 1980;73:841-843.
6. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107(23 suppl 1):I17-I21.
7. Caruso V, Iacoviello L, Di Castelnuovo A, et al. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost 2007;5:621-623.
8. Geerts WH, Bergqvist D, Pineo, GF, et al. Prevention of venous thromboembolism: american college of chest physicians evidence-based clinical practice guidelines, 8th edition. Chest 2008;133:381S-453S.
9. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: american college of chest physicians evidence-based clinical practice guidelines, 8th edition. Chest 2008;133:454S-545S.
10. Monreal M, Falgá C, Valdés M, et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006; 4: 1950-1956.
11. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-3083.
12. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000;84:805-810.
13. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488.
14. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
15. Palareti G, Cosmi B. Predicting the risk of recurrence of venous thromboembolism. Curr Opin Hematol 2004;11:192-197.
16. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-768.
17. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: american college of chest physicians evidence-based clinical practice guidelines, 8th edition. Chest 2008; 133:160S-198S.
18. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: american college of chest physicians evidence-based clinical practice guidelines, 8th edition. Chest 2008;133:141S-159S.
19. Masci G, Magagnoli M, Zucali PA, et al. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 2003;21:736-739.
20. Deitcher SR. Dalteparin reduced recurrent venous thromboembolism more than oral anticoagulation in patients with cancer. ACP J Club 2004;140:10.
21. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
22. Bona RD, Sivjee KY, Hickey AD, et al. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1995;74: 1055-1058.
23. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: american college of chest physicians evidence-based clinical practice guidelines, 8th edition. Chest 2008;133:257S-298S.
24. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-1735.
25. Zacharski LR, Prandoni P, Monreal M. Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist 2005;10: 72-79.
26. Hull R, Pineo G, Mah AF, et al, Long-term low molecular weight heparin treatment versus usual care in proximal-deep vein thrombosis patients with cancer. Am J Med 2006;119:1062-1072.
27. Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006;12:389-396.
28. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2003;1:1906-1913.
29. Ferretti G, Bria E, Giannarelli D, et al. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? Chest 2006;130:1808-1816.
30. Hull R, Pineo GF, Mah AF, et al. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer. J Throm Haemost 2003;(1 Suppl):P137a.
31. Hull R, Pineo G, Mah AF, et al. Long-term low molecular weight heparin treatment versus oral anticoagulant therapy for proximal deep vein thrombosis. Blood 2002;96:148a.
32. Walsh-McMonagle D, Green D. Low-molecular-weight heparin in the management of Trousseau's syndrome. Cancer 1997;80:649-655.
33. Eikelboom JW, Baker RI. Low-molecular-weight heparin for the treatment of venous thrombosis in patients with adenocarcinoma. Am J Hematol 1998;59:260-261.
34. Luk C, Wells PS, Anderson D, et al. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite wa-farin therapy. Am J Med 2001; 111:270-273.
35. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 1984;53:2046-2052.
36. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2129.
37. Kakkar AK, Levine M, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcomes Study (FAMOUS). J Clin Oncol 2004;22:1944-1948.
38. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135.
39. Lazo-Langner A, Goss GD, Spaans JN, et al. The effect of low molecular weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007;5:729-737.
40. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-1271.
41. Robert F, Busby E, Marques MB, et al. Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results. Lung Cancer 2003;42:237-245.
42. Cosgrove RH, Zacharski LR, Racine E, et al. Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin Thromb Hemost 2002;28:79-87.
43. Burris HA III. Low-molecular-weight hepatitis in the treatment of cancer-associated thrombosis: a new standard of care? Semin Oncol 2006;33 (2 Suppl 4): S3-S16.
44. Fragmin prescribing information. Available at: http://www.fragmin.com. Accessed November 23, 2007.
45. Elting LS, Escalante CF, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004;164:1653-1661.
46. Avritscher EB, Cantor SB, Shih YC, et al. Cost-minimization analysis of low molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis. Support Care Cancer 2004;12:531-536.
47. Ageno W, Steidl L, Marchesi C, et al. Selecting patients for home treatment of deep vein thrombosis: the problem of cancer. Haematologica 2002;87:286-291.
48. Dranitsaris G, Vincent M, Crowther M. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic vents in cancer patients: a pharmacoeconomic analysis. Pharmacoeconomics 2006;24:593-607.
49. Noble SI, Finlay IG. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 2005;19:197-201.
50. Wells PS, Kovacs MJ, Bormanis J, et al, Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998;158: 1809-1812.
51. Wittkowsky AK. Barriers to the long term use of low molecular weight heparins for the treatment of cancer-associated thrombosis. J Thromb Haemost 2006;4:2090-2091.
52. Erikkson BI, Borris L, Dahl OE, et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006;4: 121-128.
53. Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007;27:1238-1247.
54. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005;3:103-111.